GEN Exclusives

More »

GEN News Highlights

More »
Feb 11, 2010

ExonHit Joins EU’s PharmaCog Alzheimer Disease Consortium

  • ExonHit Therapeutics joined the PharmaCog project, an industry-academic partnership focused on tackling bottlenecks in Alzheimer disease research and identifying new biomarkers for the disease. The €20 million (about $27 million) PharmaCog consortium operates under the European Innovative Medicines (IMI) initiative.

    Co-ordinated by GlaxoSmithKline R&D and the Université de la Méditerranée, Marseille, France, the project includes researchers from five SMEs, 11 global pharma companies, and 12 academic institutions. The EMEA is an associate partner.

    The IMI concept was established in 2008 as a public-private collaboration between the European Pharmaceutical industry (represented by the EFPIA) and the European Commission. The initiative aims to address major logjams in drug discovery and support the faster discovery and development of new therapeutics. IMI has a total budget of €2 billion (roughly $2.7 billion) shared across multiple research projects.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?